title: Therapeutic effect of the combined use of growth hormone releasing peptide-6 and epidermal growth factor in an axonopathy model.
abstract: Amyotrophic lateral sclerosis (ALS) is a disease of the central nervous system characterized by loss of spinal motor neurons, for which no effective treatment exists. Epidermal growth factor (EGF) and growth hormone releasing peptide-6 (GHRP-6) have been considered as good candidates for the treatment of this disease, due to their well documented effects in eliciting pleiotrophic and cell survival mechanisms. The aim of the present work was to evaluate the separate and combined effects of both peptides in an experimental animal model of ALS, the proximal axonopathy induced by 1,2 diacetylbenzene (1,2 DAB) in mice. The evaluations were conducted by means of behavioral tests (trapeze, tail suspension, gait pattern, and open field) and by recording the complex muscle action potential (CMAP) in three different hind limb segments: proximal S1, medial S2, and distal S3. Intraperitoneal daily administration of 1,2 DAB produced significant reduction in body weight, muscle strength, extensor reflex, spontaneous activity, and changes in gait pattern parameters. In parallel 1,2 DAB produced significant prolongation of onset latency and decrease in amplitude of CMAP and in the integrated complex action potential index. Daily administration of the separate compounds did not accelerate the recovery of the affected parameters, except for the gait pattern. The combined treatment produced significant improvement in behavioral parameters, as well as in electrophysiological recovery, particularly in the proximal segment of CMAP. The latter results confirm the proximal character of 1,2 DAB neuropathy, and suggest that combined therapy with EGF and GHRP-6 might be a good therapeutic strategy for the treatment of ALS.
authors.affiliation: Center for Genetic Engineering and Biotechnology, Ave. 31 e/158 & 190, Cubanacan, Playa P.O. Box 6162, 10600 Havana, Cuba. diana.garcia@cigb.edu.cu
authors.forename: Diana García
authors.initials: DG
authors.lastname: Del Barco
authors.forename: Héctor
authors.initials: H
authors.lastname: Pérez-Saad
authors.forename: Valia
authors.initials: V
authors.lastname: Rodríguez
authors.forename: Javier
authors.initials: J
authors.lastname: Marín
authors.forename: Viviana
authors.initials: V
authors.lastname: Falcón
authors.forename: Jorge
authors.initials: J
authors.lastname: Martín
authors.forename: Danay
authors.initials: D
authors.lastname: Cibrian
authors.forename: Jorge
authors.initials: J
authors.lastname: Berlanga
mesh_terms: D000690:Amyotrophic Lateral Sclerosis / Q000188:drug therapy* / Q000473:pathology; D000818:Animals; D001369:Axons / Q000187:drug effects / Q000473:pathology*; D002470:Cell Survival / Q000502:physiology; D004195:Disease Models, Animal; D004359:Drug Therapy, Combination; D004815:Epidermal Growth Factor / Q000008:administration & dosage*; D005260:Female; D013007:Growth Hormone-Releasing Hormone / Q000008:administration & dosage*; D051379:Mice; D008810:Mice, Inbred C57BL; D018696:Neuroprotective Agents / Q000008:administration & dosage; D009842:Oligopeptides / Q000008:administration & dosage*
chemical_list: D018696:Neuroprotective Agents; D009842:Oligopeptides; C041048:growth hormone releasing hexapeptide; D004815:Epidermal Growth Factor; D013007:Growth Hormone-Releasing Hormone